References
- Kaye KS, Pogue JM. Infections caused by resistant gram-negative bacteria: epidemiology and management. Pharmacotherapy. 2015;35(10):949–962. doi:10.1002/phar.1636
- Minghua Z, Teng W, Wang T, et al. Long term characteristics of clinical distribution and resistance trends of carbapenem-resistant and extended-spectrum β-lactamase Klebsiella pneumoniae infections: 2014–2022. Infect Drug Resist. 2023;16:1.
- Lu T, Quan JJ, Wang YF, et al. Prevalence of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections from county hospitals of Zhejiang Province. Chin J Infect Dis. 2017;35(4):198–202.
- Emel M-K, Mesut Y, Berna Ö-Ç. In vitro synergistic effect and mutant prevention concentrations of cefepime alone or in combination with sulbactam against OXA-48-positive Klebsiella pneumoniae isolates. Curr Microbiol. 2020;77(9):1.
- Mataracı-Kara E, Özbek-çelik B, Yılmaz M, et al. In vitro synergistic effect and mutant prevention concentrations of cefepime alone or in combination with sulbactam against OXA-48-positiveKlebsiellapneumoniaeIsolates. Curr Microbiol. 2020;77(9):2137–2142. doi:10.1007/s00284-020-02094-0
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI; 2018.
- An G, Creech CB, Wu N, et al. Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients. J Antimicrob Chemoth. 2023;78(6):1460–1470. doi:10.1093/jac/dkad106
- Yang F, Chen P, Wang H. Comparative minimal inhibitory and mutant prevention concentration of eight antimicrobial agents against Klebsiella pneumoniae. Microb Drug Resist. 2022;28(2):229–235. doi:10.1089/mdr.2021.0228
- Brennan-Krohn TAS, Kenneth P, James E, Kirby JE. Improved accuracy of cefepime susceptibility testing for extended-spectrum-beta-lactamase-producing Enterobacteriaceae with an on-demand digital dispensing method. J Clin Microbiol. 2017;55(2):470–478. doi:10.1128/JCM.02128-16
- Martinez-Martinez L, Conejo MC, Pascual A, et al. Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal β-lactamase and showing altered porin profiles. Antimicrob Agents Chemother. 2000;44(9):2534–2536. doi:10.1128/AAC.44.9.2534-2536.2000
- Edelberto S. Pharmacokinetics and pharmacodynamics of cefepime in adults with hematological malignancies and febrile neutropenia after chemotherapy. Antibiotics. 2021;10(5):1.
- Christopher M, Brian E, Kirby J, et al. Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Escherichia coli and Klebsiella pneumoniae. Int J Antimicrob Agents. 2023;61(5):106762. doi:10.1016/j.ijantimicag.2023.106762
- Melika M, Yasmine E. Intestinal colonization with multidrug-resistant Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers. Eur J Clin Microbiol Infect Dis. 2023;42(3):1.
- Clasen J, Birkegård AC, Græsbøll K, Folkesson A. Evolution of TEM-type extended-spectrum β-lactamases in Escherichia coli by cephalosporins. J Glob Antimicrob Res. 2019;19:32–39. doi:10.1016/j.jgar.2019.03.010
- Aubert D, Pairel L, Chevalier J, Leotard S, Pages J-M, Nordmann P. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001;45:16151620. doi:10.1128/AAC.45.6.1615-1620.2001
- Li Z, Feng S, Sun G, et al. Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease. Infect Drug Resist. 2019;12:481–491. doi:10.2147/IDR.S191462
- Mizrahi A, Chat L, Danjean M, et al. Inoculum effect of Enterobacterales co-expressing OXA-48 and CTX-M on the susceptibility to ceftazidime/avibactam and meropenem. Eur J Clin Microbiol. 2022;41(5):853–858. doi:10.1007/s10096-022-04430-7